| Title |
Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers
|
|---|---|
| Published in |
Current Treatment Options in Cardiovascular Medicine, March 2018
|
| DOI | 10.1007/s11936-018-0609-z |
| Pubmed ID | |
| Authors |
Kelly C. Gast, Paul V. Viscuse, Somaira Nowsheen, Tufia C. Haddad, Robert W. Mutter, Andrea E. Wahner Hendrickson, Fergus J. Couch, Kathryn J. Ruddy |
| Abstract |
BRCA1 and BRCA2 mutation carriers can be at increased cardiovascular risk. The goal of this review is to provide information about factors associated with increased cardiovascular risk, methods to prevent cardiovascular toxicities, and recommended screening guidelines. BRCA1/2 mutation carriers who are diagnosed with cancer are often exposed to chemotherapy, chest radiotherapy, and/or HER2 directed therapies, all of which can be cardiotoxic. In addition, BRCA1/2 carriers often undergo prophylactic salpingoopherectomies, which may also increase cardiovascular risks. Understanding the potential for increased cardiovascular risk in individuals with a BRCA1 or BRCA2 mutation, as well as gold standard practices for prevention, detection, and treatment of cardiac concerns in this population, is important. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 43% |
| Canada | 2 | 29% |
| Unknown | 2 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 20 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 15% |
| Librarian | 2 | 10% |
| Student > Ph. D. Student | 2 | 10% |
| Researcher | 2 | 10% |
| Other | 1 | 5% |
| Other | 4 | 20% |
| Unknown | 6 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 25% |
| Biochemistry, Genetics and Molecular Biology | 2 | 10% |
| Neuroscience | 2 | 10% |
| Psychology | 1 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Other | 2 | 10% |
| Unknown | 7 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2018.
All research outputs
#7,299,930
of 23,025,074 outputs
Outputs from Current Treatment Options in Cardiovascular Medicine
#147
of 416 outputs
Outputs of similar age
#128,130
of 331,156 outputs
Outputs of similar age from Current Treatment Options in Cardiovascular Medicine
#8
of 21 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 416 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,156 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.